A random controlled study of the prophylactic effect of lysozyme chloride on post-transfusion hepatitis.
In a study designed to determine the preventive effect of lysozyme on post-transfusion hepatitis, 260 patients with orthopedic diseases, who received blood by transfusion during a period of 5 years from June 1970 to May 1975, were divided at random into a group of 123 patients treated with lysozyme is doses of 60 to 170 mg/day for 4 to 24 weeks, and a control group of 137 patients. The incidence of post-transfusion hepatitis was 10 (8.1%) out of 123 patients for the treated group, and 28 (20.4%) out of 137 patients for the control group. Icteric hepatitis occurred in 1 (0.8%) patient in the treated group, while its incidence in the control group was 8 (5.8%) out of 137 patients.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006509:Hepatitis B / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009113:Muramidase / Q000627:therapeutic use*; D011897:Random Allocation; D065227:Transfusion Reaction
D009113:Muramidase